Table 3.
Descriptive information (top half of table) and correlations (bottom half of table) for the moderators of interest.
| Descriptive information | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Abstinence before trial | Detoxification before trial | Goal of treatment | Length of treatment | Dosage | |||||||
| Required (k) | Not Required (k) | Length (days)a | Required (k) | Not Required (k) | Abstinence (k) | Other (k) | Average length (days) | 50 mg (k) | 100+ mg (k) | Other (k) | |
| Naltrexone | 30 | 18 | M = 3.87 (SD = 5.05) | 8 | 40 | 24 | 26 | M = 96.83 (SD = 57.96) | 39 | 8 | 2 |
| 1998 mg (k) | By weight (k) | Other (k) | |||||||||
| Acamprosate | 16 | 3 | M = 6.21 (SD = 5.49) | 13 | 6 | 13 | 6 | M = 173.37 (SD = 107.96) | 7 | 8 | 4 |
| Correlations among moderators | ||||
|---|---|---|---|---|
| Length of required abstinence | Detoxification before trial | Goal of treatment | Length of treatment | |
| Length of required abstinence | -- | -- | -- | -- |
| Detoxification before trial | Naltrex:br = 0.60**, 0.52** Acamp:cr = 0.59** |
-- | -- | -- |
| Goal of treatment | Naltrex: r = 0.28+, 0.36* Acamp: r = 0.30 |
Naltrex: r = −0.04, 0.03 Acamp: r = 0.32 |
-- | -- |
| Length of treatment | Naltrex: r = 0.22, 0.22 Acamp: r = 0.09 |
Naltrex: r = −0.08, −0.10 Acamp: r = 0.36 |
Naltrex: r = 0.18, 0.21 Acamp: r = 0.33 |
-- |
| Dosage | Naltrex: r = −0.09, −0.18 Acamp: r = 0.18 |
Naltrex: r = −0.20, −0.15 Acamp: r = 0.28 |
Naltrex: r = 0.11, 0.03 Acamp: r = 0.04 |
Naltrex: r = 0.03, −0.11 Acamp: r = 0.36 |
Notes.
+
p < .10
*
p < .05
**
p < .01.
k = number of studies.
a
Minimum length of required abstinence. If abstinence not required, length = 0 days.
b
To accurately assess collinearity in specific analyses, correlations are for the naltrexone studies in abstinence moderator analyses (k = 39) and heavy drinking moderator analyses (k = 42), respectively.
c
Correlations are for acamprosate studies in abstinence moderator analyses (k = 18).